Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 dose-escalation study of RAD1901 in healthy postmenopausal women
NL-OMON41865Phase 1Active, not recruiting
- Sponsor
- Radius Health Inc
- Start
- Jun 2014
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in breast cancer and brain metastases comparing RAD1901 with Placebo (2 arms). Primary endpoint: Maximum tolerated dose, safety, tolerability, and pharmacokinetics of RAD1901. Started Jun 2014; status: active, not recruiting.
02
Drugs
elacestrant
03
Conditions
breast cancerbrain metastases
Beyond the preview
Go deeper on NL-OMON41865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41865.